Bayer And Novartis Lose Challenge To NHS Eye Drug Policy

Law360, London (March 25, 2020, 10:16 PM GMT) -- The Court of Appeal ruled Wednesday that a policy from certain NHS groups offering an off-label drug for treatment of an eye disorder was lawful, rejecting Bayer and Novartis' arguments that permitting use of the unlicensed medicine undermines European safety standards.

The decision affirms a lower court judge's ruling in favor of 12 National Health Service clinical commissioning groups, which adopted a policy recommending that clinicians offer patients who suffer from the eye disease be given a choice between licensed medicines marketed by the two pharmaceutical giants and a cheaper drug called Avastin that was originally developed and approved by the European Union...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!